Groupama Asset Managment Sells 6,125 Shares of Agilent Technologies, Inc. $A

Key Points

• Groupama Asset Management reduced its stake in Agilent Technologies by 47.7% during the first quarter, selling 6,125 shares and holding 6,709 shares worth approximately $783,000.
• Several hedge funds increased their stakes in Agilent, with Mirae Asset Global Investments raising its position by 13.5% and D.A. Davidson & CO. increasing its stake by 30.4% in the same period.
• Agilent Technologies reported a Q2 earnings per share (EPS) of $1.31, beating expectations, and expects to post EPS guidance of 5.58 for the current year.

Groupama Asset Managment decreased its holdings in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 47.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,709 shares of the medical research company's stock after selling 6,125 shares during the quarter. Groupama Asset Managment's holdings in Agilent Technologies were worth $783,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Agilent Technologies by 13.5% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company's stock worth $4,279,000 after purchasing an additional 4,362 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in Agilent Technologies by 8.3% during the first quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company's stock worth $3,606,000 after purchasing an additional 2,371 shares during the last quarter. Alps Advisors Inc. boosted its holdings in Agilent Technologies by 29.5% during the first quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company's stock worth $1,563,000 after purchasing an additional 3,040 shares during the last quarter. D.A. Davidson & CO. boosted its holdings in Agilent Technologies by 30.4% during the first quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company's stock worth $1,108,000 after purchasing an additional 2,207 shares during the last quarter. Finally, LGT Capital Partners LTD. boosted its holdings in Agilent Technologies by 7.6% during the first quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company's stock worth $89,870,000 after purchasing an additional 54,302 shares during the last quarter.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. TD Cowen increased their target price on shares of Agilent Technologies to $150.00 and gave the stock a "buy" rating in a report on Thursday, May 29th. JPMorgan Chase & Co. cut their price target on shares of Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating for the company in a research note on Thursday, May 29th. UBS Group cut their price target on shares of Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating for the company in a research note on Thursday, May 29th. Robert W. Baird cut their price target on shares of Agilent Technologies from $159.00 to $140.00 and set an "outperform" rating for the company in a research note on Thursday, May 22nd. Finally, Barclays increased their price target on shares of Agilent Technologies from $115.00 to $125.00 and gave the company an "equal weight" rating in a research note on Tuesday, June 24th. Seven investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $139.77.

Agilent Technologies Trading Up 3.7%

NYSE:A traded up $4.3420 during mid-day trading on Friday, hitting $121.4920. 1,290,972 shares of the company's stock were exchanged, compared to its average volume of 1,284,543. The firm has a market capitalization of $34.51 billion, a P/E ratio of 30.00, a PEG ratio of 3.69 and a beta of 1.22. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $153.84. The company has a current ratio of 2.09, a quick ratio of 1.60 and a debt-to-equity ratio of 0.55. The company has a 50 day simple moving average of $117.88 and a 200-day simple moving average of $117.26.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings results on Wednesday, May 28th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.26 by $0.05. The firm had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.63 billion. Agilent Technologies had a net margin of 17.59% and a return on equity of 25.92%. The company's revenue for the quarter was up 6.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.22 EPS. Agilent Technologies has set its FY 2025 guidance at 5.540-5.610 EPS. Q3 2025 guidance at 1.350-1.370 EPS. As a group, research analysts expect that Agilent Technologies, Inc. will post 5.58 earnings per share for the current year.

Insider Activity

In other news, CEO Padraig Mcdonnell sold 1,508 shares of the business's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total value of $177,099.52. Following the transaction, the chief executive officer owned 37,448 shares in the company, valued at approximately $4,397,893.12. The trade was a 3.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.